cyclosporine has been researched along with Macrophage Activation Syndrome in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.70) | 29.6817 |
| 2010's | 25 (67.57) | 24.3611 |
| 2020's | 11 (29.73) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, AS; Abdel-Aziz, TM; Alsaqabi, F; Gouda, W; Islam, MA; Moshrif, A | 1 |
| Hiratoko, K; Inoue, M; Kanamori, T; Mori, M; Morio, T; Mouri, M; Nishino, I; Okiyama, N; Okubo, M; Shimizu, M; Tanaka, E | 1 |
| Iwata, N; Kaneko, U; Kinjo, N; Kubota, T; Mizuta, M; Mori, M; Mouri, M; Nakagishi, Y; Nishimura, K; Okamoto, N; Okura, Y; Shimizu, M; Umebayashi, H; Wakiguchi, H; Yashiro, M; Yasumi, T; Yasumura, J | 1 |
| Jia, Y; Li, ZG; Wang, YN; Wang, Z; Yao, HH; Zhang, X; Zhao, JX | 1 |
| Einwächter, H; Heemann, U; Küchle, C; Lorenz, G; Moog, P; Riedhammer, KM; Schmaderer, C; Schraml, F; Schul, L; Slotta-Huspenina, J; Verbeek, M | 1 |
| Garrido-García, LM; Iglesias-Amaya, A; Moreno-Espinosa, S; Pardo-Díaz, E; Rivera-Rodriguez, L; Ruiz-Ontiveros, MA; Scheffler-Mendoza, S; Yamazaki-Nakashimada, MA | 1 |
| Bose, N; Chowdhury, K; Pal, P; Poddar, A; Saha, A | 1 |
| Bathia, J; Giri, PP; Nandi, A; Pal, P; Roy, M | 1 |
| Maeda, S; Naniwa, T; Ohmura, SI; Tamechika, S; Uehara, K; Yamabe, T | 1 |
| Ding, Y; Fang, H; Hu, Y; Li, S; Qiao, J; Sun, C; Tang, S; Zheng, S; Zhu, D | 1 |
| Kanegane, H; Kong, P; Tang, X; Yan, X; Yang, X; Yao, H; Zhang, X; Zhang, Z; Zhao, Q; Zhao, X | 1 |
| Banday, A; Bansal, R; Jindal, AK; Loganathan, S; Mohanandia, B; Patra, N; Pulipaka, S; Singh, S; Sudhakar, M | 1 |
| Báez, M; Borjas-Aguilar, KL; García-Pavón, S; Murata, C; Yamazaki-Nakashimada, MA | 1 |
| Aleem, S; Ballas, ZK; Kumar, B; Petts, J; Saleh, H | 1 |
| Bader-Meunier, B; Bodemer, C; Brochard, K; Fraitag, S; Janssen, C; Lamant, L; Wouters, C | 1 |
| Ben-Chetrit, E; Tayer-Shifman, OE | 1 |
| Komagata, Y | 1 |
| Alessio, M; Anton, J; Avcin, T; Bovis, F; Chasnyk, V; Cron, RQ; Davì, S; Demirkaya, E; Espada, G; Fischbach, M; Frosch, M; Gao, YJ; Grom, A; Horne, A; Huasong, Z; Huber, A; Insalaco, A; Jelusic, M; Kasapcopur, O; Khubchandani, R; Kitoh, T; Lehmberg, K; Li, C; Maritsi, D; Martini, A; Merino, R; Miettunen, P; Minoia, F; Ozen, S; Pal, P; Ravelli, A; Ruperto, N; Russo, R; Sanner, H; Sawhney, S; Shakoory, B; Shenoi, S; Uziel, Y; Weitzman, S; Wouters, C | 1 |
| Grom, AA; Schulert, GS | 1 |
| Jeong, DC; Kim, HJ; Kim, SH; Kim, SY; Lee, SJ; Park, JH | 1 |
| Bailhache, M; Berciaud, S; Lagarde, M; Pillet, P; Richer, O | 1 |
| Wagner-Weiner, L | 1 |
| Hasegawa, S; Hirano, R; Kaneyasu, H; Ohga, S; Wakabayashi-Takahara, M; Wakiguchi, H | 1 |
| Anton, J; Boom, V; Lahdenne, P; Quartier, P; Ravelli, A; Vastert, SJ; Wulffraat, NM | 1 |
| Lenert, A; Yao, Q | 1 |
| Aytaç, S; Batu, ED; Bilginer, Y; Çetin, M; Gümrük, F; Özen, S; Tuncer, M; Ünal, Ş | 1 |
| Jiang, N; Li, MT; Wu, D; Zeng, XF | 1 |
| Anić, B; Barešić, M; Gjadrov-Kuveždić, K; Janka, GE; Zekan, Š | 1 |
| Abdelhaleem, M; Benseler, S; Gupta, AA; Tyrrell, P; Valani, R; Weitzman, S | 1 |
| Kaneko, H; Kobayashi, M; Mimori, A; Takahashi, Y; Yamashita, H | 1 |
| Bracaglia, C; Buonuomo, PS; Campana, A; Cortis, E; Insalaco, A; Pardeo, M | 1 |
| George, AM; Ittycheria, CC; Jacob, AG; Jacob, CN; Jayaprakash, R; John, TM; Puthiyaveettil, J; Subramaniyam, S | 1 |
| Behrens, EM; Cron, RQ; Grom, AA; Ravelli, A | 1 |
| Besbas, N; Bilginer, Y; Cetin, M; Gokce, M; Gumruk, F; Ozaltin, F; Ozen, S | 1 |
| Chiang, BL; Lee, JH; Lin, CI; Lin, YT; Wang, LC; Yang, YH; Yu, HH | 1 |
| Bayrakci, B; Carcillo, JA; Citak, A; Demirkol, D; Dursun, O; Erkek, N; Gedik, H; Karabocuoglu, M; Karapinar, B; Kendirli, T; Kesici, S; Koroglu, TF; Yildizdas, D | 1 |
| Bennett, TD; Bratton, SL; Brogan, TV; Casper, TC; Fluchel, M; Hayward, KN; Hersh, AL; Hersh, AO; Korgenski, EK; Mundorff, MB; Srivastava, R; Stone, BL | 1 |
8 review(s) available for cyclosporine and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.
Topics: Adenoviridae; Adenoviridae Infections; Antiviral Agents; Arthritis, Juvenile; Child, Preschool; Cidofovir; Combined Modality Therapy; Cyclosporine; Female; Humans; Macrophage Activation Syndrome; Methylprednisolone; Pneumonia, Viral; Radiography, Thoracic | 2020 |
Understanding of cytokines and targeted therapy in macrophage activation syndrome.
Topics: Adult; Arthritis, Juvenile; Cyclosporine; Cytokines; Humans; Macrophage Activation Syndrome; Still's Disease, Adult-Onset | 2021 |
Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal; Aspartate Aminotransferases; Child; Child, Preschool; Coronary Vessel Anomalies; Cyclosporine; Etoposide; Female; Fever; Humans; Infant; Macrophage Activation Syndrome; Male; Mucocutaneous Lymph Node Syndrome; Tumor Necrosis Factor-alpha | 2017 |
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 4. Macrophage activating syndrome and
Topics: Antirheumatic Agents; Connective Tissue Diseases; Cyclosporine; Dexamethasone; Drug Therapy, Combination; Etoposide; gamma-Globins; Humans; Immunosuppressive Agents; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Methotrexate; Methylprednisolone; Pulse Therapy, Drug | 2013 |
Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.
Topics: Adrenal Cortex Hormones; Cyclosporine; Cytokines; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Macrophage Activation Syndrome; Molecular Targeted Therapy | 2015 |
Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
Topics: Antirheumatic Agents; Arthralgia; Arthritis, Juvenile; Child; Cyclosporine; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Macrophage Activation Syndrome; Prednisone | 2015 |
Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Biomarkers; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome | 2015 |
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.
Topics: Adrenal Cortex Hormones; Animals; Antirheumatic Agents; Arthritis, Juvenile; Child; Cyclosporine; Disease Models, Animal; Humans; Interleukin 1 Receptor Antagonist Protein; Macrophage Activation Syndrome; Mice; Mutation; Receptors, Interleukin-1; Receptors, Interleukin-10; Toll-Like Receptor 9 | 2012 |
29 other study(ies) available for cyclosporine and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Macrophage activation syndrome triggered by systemic lupus erythematosus flare: successful treatment with a combination of dexamethasone sodium phosphate, intravenous immunoglobulin, and cyclosporine: a case report.
Topics: Adult; Cyclosporine; Dexamethasone; Female; Humans; Immunoglobulins, Intravenous; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Methylprednisolone | 2021 |
Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developed during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report.
Topics: Child, Preschool; Cyclophosphamide; Cyclosporine; Dermatomyositis; Hepatic Veno-Occlusive Disease; Humans; Macrophage Activation Syndrome; Male; Thrombotic Microangiopathies | 2023 |
Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan.
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Child; Cyclosporine; Humans; Japan; Macrophage Activation Syndrome; Retrospective Studies | 2023 |
[Clinical characteristics and treatment outcomes of macrophage activation syndrome in adults: A case series of 67 patients].
Topics: Adult; Cyclosporine; Humans; Macrophage Activation Syndrome; Middle Aged; Retrospective Studies; Still's Disease, Adult-Onset; Treatment Outcome; Young Adult | 2019 |
Adult macrophage activation syndrome-haemophagocytic lymphohistiocytosis: 'of plasma exchange and immunosuppressive escalation strategies' - a single centre reflection.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cyclosporine; Cytokines; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Middle Aged; Plasma Exchange; Retrospective Studies; Sepsis; Still's Disease, Adult-Onset; Young Adult | 2020 |
Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
Topics: Adrenal Cortex Hormones; Adult; Child, Preschool; Cyclosporine; Dermatologic Agents; Female; Humans; Immunoglobulins, Intravenous; Infliximab; Macrophage Activation Syndrome; Male; Mucocutaneous Lymph Node Syndrome; Young Adult | 2021 |
Macrophage activation syndrome in pediatrics: 10 years data from an Indian center.
Topics: Arthritis, Juvenile; Child, Preschool; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Glucocorticoids; Hospitals, Pediatric; Humans; Immunosuppressive Agents; Incidence; India; Macrophage Activation Syndrome; Male; Methylprednisolone; Retrospective Studies | 2020 |
Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide.
Topics: Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Etoposide; Glucocorticoids; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Molecular Targeted Therapy; Severity of Illness Index; Still's Disease, Adult-Onset; Treatment Outcome | 2020 |
UNC13D mutation in a patient with juvenile polymyositis with recurrent macrophage activation syndrome.
Topics: Adolescent; Antirheumatic Agents; Autoantibodies; Bone Marrow Examination; Cyclosporine; Etoposide; Homozygote; Humans; Macrophage Activation Syndrome; Male; Membrane Proteins; Methylprednisolone; Mutation, Missense; Patient Care Planning; Polymyositis; Positron Emission Tomography Computed Tomography; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2021 |
Tapering Doses of Methylprednisolone Pulse in the Treatment of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis.
Topics: Arthritis, Juvenile; Cyclosporine; Heart Rate; Humans; Macrophage Activation Syndrome; Methylprednisolone | 2021 |
A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Cyclosporine; Cytokines; Female; Humans; Immunoglobulins; Immunologic Factors; Interleukin 1 Receptor Antagonist Protein; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Middle Aged; Precision Medicine; Steroids; Treatment Outcome; Young Adult | 2017 |
Clonal cytophagic histiocytic panniculitis in children may be cured by cyclosporine A.
Topics: Biopsy, Needle; Bone Marrow; Chickenpox; Cyclosporine; Diagnosis, Differential; Female; Histiocytosis; Humans; Immunosuppressive Agents; Infant; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Macrophage Activation Syndrome; Male; Panniculitis; Respiratory Tract Infections; T-Lymphocytes | 2013 |
Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome - Successful use of PET- CT and Anakinra in its diagnosis and treatment.
Topics: Adult; Antiphospholipid Syndrome; Antirheumatic Agents; Cyclosporine; Female; Humans; Interleukin 1 Receptor Antagonist Protein; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Biological Products; Child; Child, Preschool; Cohort Studies; Cyclosporine; Etoposide; Female; Fever; Hepatomegaly; Humans; Intensive Care Units; International Cooperation; Macrophage Activation Syndrome; Male; Prevalence; Retrospective Studies; Splenomegaly; Survival Rate; Treatment Outcome | 2014 |
Macrophage activation syndrome in a newborn infant born to a mother with autoimmune disease.
Topics: Adult; Antirheumatic Agents; Cyclosporine; Early Diagnosis; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Infant, Newborn; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Maternal-Fetal Exchange; Pregnancy; Still's Disease, Adult-Onset; Treatment Outcome | 2015 |
[Macrophage activation syndrome: diagnosis and emergency management].
Topics: Biological Products; Child; Cyclosporine; Glucocorticoids; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome | 2015 |
Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child, Preschool; Cyclosporine; Cytokines; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Interleukin-18; Interleukin-6; Lung Diseases, Interstitial; Macrophage Activation Syndrome | 2015 |
Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Topics: Adult; Cyclosporine; Disseminated Intravascular Coagulation; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Liver Diseases; Lung Diseases; Macrophage Activation Syndrome; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Serositis; Shock; Still's Disease, Adult-Onset; Young Adult | 2016 |
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis, Juvenile; Child; Child, Preschool; Cyclosporine; Fatigue; Female; Humans; Immunosuppressive Agents; Infant; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Male; Retrospective Studies; Treatment Outcome | 2016 |
[The clinical characteristics of macrophage activation syndrome secondary to systemic lupus erythematosus].
Topics: Adult; Cyclophosphamide; Cyclosporine; Female; Fever; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Visceral leishmaniasis triggering (mimicking) macrophage activation syndrome in a patient with adult onset Still disease.
Topics: Adult; Bone Marrow; Cyclosporine; Diagnosis, Differential; Humans; Leishmaniasis, Visceral; Macrophage Activation Syndrome; Male; Prednisone; Still's Disease, Adult-Onset | 2016 |
Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution.
Topics: Adolescent; Adrenal Cortex Hormones; Cause of Death; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematologic Neoplasms; Humans; Immunoglobulins, Intravenous; Infant; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Retrospective Studies; Rheumatic Diseases; Steroids; Virus Diseases | 2009 |
Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Liposomes; Macrophage Activation Syndrome; Middle Aged; Risk Assessment; Still's Disease, Adult-Onset; Treatment Outcome | 2011 |
Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.
Topics: Child, Preschool; Cyclosporine; Etanercept; Fasciitis, Necrotizing; Humans; Immunoglobulin G; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Receptors, Tumor Necrosis Factor; Risk Factors | 2013 |
Macrophage activation syndrome following Acinetobacter baumannii sepsis.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Colistin; Cyclosporine; Drug Resistance, Multiple, Bacterial; Humans; Macrophage Activation Syndrome; Male; Polymyxins; Prednisolone; Sepsis | 2012 |
Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children.
Topics: Adolescent; Anemia, Hemolytic; Antibodies; Anticoagulants; Antiphospholipid Syndrome; Cardiolipins; Child; Child, Preschool; Cyclosporine; Female; Heparin, Low-Molecular-Weight; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Leukopenia; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Male; Phospholipids; Plasma Exchange; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Steroids; Thrombotic Microangiopathies; Venous Thrombosis | 2012 |
Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.
Topics: Adolescent; Antiphospholipid Syndrome; Arthritis, Juvenile; Autoimmune Diseases; Child; Cyclosporine; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Male; Methylprednisolone; Retrospective Studies; Treatment Outcome | 2012 |
Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Combined Modality Therapy; Critical Illness; Cyclosporine; Dexamethasone; Etoposide; Female; Ferritins; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Iron Overload; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Multiple Organ Failure; Plasma Exchange; Prednisolone; Regression Analysis; Sepsis; Survival Rate; Treatment Outcome; Turkey | 2012 |
Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis.
Topics: Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cyclosporine; Female; Hospital Mortality; Humans; Infant; Infant, Newborn; Inpatients; Intensive Care Units, Pediatric; Interleukin-1; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Male; Mycophenolic Acid; Retrospective Studies; Treatment Outcome | 2012 |